All In Biotech

Drug Trial Radar · NCT05142774

Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis

An Open-Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Tapinarof Cream, 1% in Subjects With Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Aug 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

728

Actual

Start

Oct 28, 2021

Primary completion

Feb 29, 2024

Study completion Mar 7, 2024

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Dec 3, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, long-term multicenter, study to evaluate the safety and efficacy of topical tapinarof cream, 1% in subjects with atopic dermatitis. Subjects in this study have completed treatment in one of two Phase 3 pivotal studies (DMVT-505-3101 or DMVT-505-3102) or completed treatment in the DMVT-505-2104 study, or directly enrolled into this study. This study will consist of up to 48 weeks of treatment and a 1 week safety follow-up period.

Conditions

  • Atopic Dermatitis

Interventions

  • Tapinarof cream, 1%Drug

    Tapinarof cream, 1%, applied daily to affected areas by subjects or their caregivers based on vIGA-AD. Subjects are advised to choose the application time they prefer and apply the study drug at that approximate time each day of study participation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects With Treatment-Emergent Adverse Events (TEAE) and Serious Adverse EventsTime frame: Baseline to Week 49
  2. Frequency of Adverse Events and Serious Adverse EventsTime frame: Baseline to Week 49
  3. Change From Baseline in Clinical Laboratory Values (g/L)Time frame: Baseline to Week 48
  4. Change From Baseline in Clinical Laboratory Values (U/L)Time frame: Baseline to Week 48
  5. Change From Baseline in Clinical Laboratory Values (mmol/L)Time frame: Baseline to Week 48
  6. Change From Baseline in Clinical Laboratory Values (Umol/L)Time frame: Baseline to Week 48
  7. Change From Baseline in Clinical Laboratory Values (10^9 Cells/L)Time frame: Baseline to Week 48
  8. Change From Baseline in Clinical Laboratory Values (%)Time frame: Baseline to Week 48
  9. Change From Baseline in Clinical Laboratory Values (L/L)Time frame: Baseline to Week 48
  10. Change From Baseline in Clinical Laboratory Values (pg)Time frame: Baseline to Week 48
  11. Change From Baseline in Clinical Laboratory Values (fl)Time frame: Baseline to Week 48
  12. Change From Baseline in Clinical Laboratory Values (10^12 Cells/L)Time frame: Baseline to Week 48
  13. Complete Disease Clearance During LTE: Number of Subjects Achieving Disease Clearance vIGA-AD =0 (Clear) While on Therapy for Subjects Entered LTE vIGA-AD ≥ 1 (Almost Clear )Time frame: Baseline to Week 48
  14. Response During LTE: Number of Subjects Achieving vIGA-AD =0 or 1 (Clear or Almost Clear) While on Therapy for Subjects Who Entered LTE With vIGA-AD ≥ 2 (Mild)Time frame: Baseline to Week 48
  15. Absolute Change From Baseline in %BSA AffectedTime frame: Baseline to Week 48
  16. Percent Change From Baseline in %BSA AffectedTime frame: Baseline to Week 48
  17. Mean Change From Baseline in Eczema Area and Severity Index (EASI) ScoreTime frame: Baseline to Week 48
  18. Percent Change From Baseline in Eczema Area and Severity Index (EASI) ScoreTime frame: Baseline to Week 48
  19. Percent of Subjects With ≥ 50% Improvement in Eczema Area and Severity Index (EASI) From Baseline at Week 48.Time frame: Baseline to Week 48
  20. Percent of Subjects With ≥ 75% Improvement in Eczema Area and Severity Index (EASI) From Baseline at Week 48.Time frame: Baseline to Week 48
  21. Percent of Subjects With ≥ 90% Improvement in Eczema Area and Severity Index (EASI) From Baseline at Week 48.Time frame: Baseline to Week 48
  22. Mean Change in Peak Pruritis-Numeric Rating Scale (PP-NRS) From BaselineTime frame: Baseline to Week 48
  23. Number of Subjects With a Baseline Peak Pruritis-Numeric Rating Scale (PP-NRS) Score ≥ 4 Who Achieve ≥ 4-point Reduction in the PP-NRS From BaselineTime frame: Baseline to Week 48
  24. Change From Baseline in Vital Signs - PulseTime frame: Baseline to Week 48
  25. Change From Baseline in Vital Signs - Blood Pressure (Systolic and Diastolic)Time frame: Baseline to Week 48
  26. Change From Baseline in Vital Signs - TemperatureTime frame: Baseline to Week 48

Locations

112 sites in 2 countries. Site status is shown where the registry gives one.

  • Dermavant Investigative Site

    Birmingham, Alabama

  • Dermavant Investigative Site

    Phoenix, Arizona

  • Dermavant Investigative Site

    Scottsdale, Arizona

  • Dermavant Investigative Site

    Scottsdale, Arizona

  • Dermavant Investigative Site

    Bryant, Arkansas

  • Dermavant Investigative Site

    Fort Smith, Arkansas

  • Dermavant Investigative Site

    Cerritos, California

  • Dermavant Investigative Site

    Fountain Valley, California

  • Dermavant Investigative Site

    Fremont, California

  • Dermavant Investigative Site

    Huntington Beach, California

  • Dermavant Investigative Site

    Inglewood, California

  • Dermavant Investigative Site

    Lancaster, California

  • Dermavant Investigative Site

    Long Beach, California

  • Dermavant Investigative Site

    Los Angeles, California

  • Dermavant Investigative Site

    Los Angeles, California

  • Dermavant Investigative Site

    Los Angeles, California

  • Dermavant Investigative Site

    Mission Viejo, California

  • Dermavant Investigative Site

    Sacramento, California

  • Dermavant Investigative Site

    San Diego, California

  • Dermavant Investigative Site

    San Francisco, California

  • Dermavant Investigative Site

    Santa Ana, California

  • Dermavant Investigative Site

    Santa Monica, California

  • Dermavant Investigative Site

    Thousand Oaks, California

  • Dermavant Investigative Site

    Thornton, Colorado

  • Dermavant Investigative Site

    Washington D.C., District of Columbia

  • Dermavant Investigative Site

    Boca Raton, Florida

  • Dermavant Investigative Site

    Boca Raton, Florida

  • Dermavant Investigative Site

    Brandon, Florida

  • Dermavant Investigative Site

    Coral Gables, Florida

  • Dermavant Investigative Site

    Delray Beach, Florida

  • Dermavant Investigative Site

    Hialeah, Florida

  • Dermavant Investigative Site

    Jacksonville, Florida

  • Dermavant Investigative Site

    Margate, Florida

  • Dermavant Investigative Site

    Miami, Florida

  • Dermavant Investigative Site

    Miami, Florida

  • Dermavant Investigative Site

    Miami Lakes, Florida

  • Dermavant Investigative Site

    Orlando, Florida

  • Dermavant Investigative Site

    Pinellas Park, Florida

  • Dermavant Investigative Site

    Sweetwater, Florida

  • Dermavant Investigative Site

    Tampa, Florida

Showing 40 of 112 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.